Showing results (881-890 of 3,354) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
The Lancet. Oncology|January 1, 2022
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancerIcro Meattini, Carlotta Becherini, Liesbeth Boersma, et al.
The Lancet. Oncology|January 1, 2022
Clinical advances in PET-MRI for breast cancerAmy M Fowler, Roberta M Strigel
The Lancet. Oncology|January 20, 2022
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Holly Hartman, et al.
The Lancet. Oncology|February 28, 2014
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trialPeter J Hoskin, Amy A Kirkwood, Bilyana Popova, et al.
The Lancet. Oncology|October 16, 2009
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trialNatacha Heutte, Henning H Flechtner, Nicolas Mounier, et al.
The Lancet. Oncology|June 21, 2011
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort studyAlessandro Vitale, Rafael Ramirez Morales, Giacomo Zanus, et al.
The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
The Lancet. Oncology|September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataAngelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
The Lancet. Oncology|September 16, 2011
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studiesXavier Castellsagué, Mireia Díaz, Salvatore Vaccarella, et al.
Pageof 336